
    
      A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of
      GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID)
      when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose
      Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks
    
  